AKT1 and breast carcinoma: Furthermore, by using human breast cancer cell lines and a series of breast cancer biopsies from patients undergoing tamoxifen therapy, it was found that α6β4 integrin contributes to tamoxifen resistance via induction of ErbB-3 expression, which leads to an increase in AKT activation [44].